Vestmark Advisory Solutions Inc. Decreases Position in Haleon PLC Sponsored ADR $HLN

Vestmark Advisory Solutions Inc. lessened its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 53.6% during the third quarter, HoldingsChannel reports. The firm owned 68,712 shares of the company’s stock after selling 79,481 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Haleon were worth $616,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Citigroup Inc. lifted its position in shares of Haleon by 7.0% during the 3rd quarter. Citigroup Inc. now owns 986,450 shares of the company’s stock valued at $8,848,000 after buying an additional 64,298 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Haleon in the 3rd quarter valued at about $103,000. King Luther Capital Management Corp lifted its holdings in Haleon by 4.4% during the third quarter. King Luther Capital Management Corp now owns 28,292 shares of the company’s stock valued at $254,000 after purchasing an additional 1,204 shares during the last quarter. NewEdge Wealth LLC boosted its position in Haleon by 20.0% during the third quarter. NewEdge Wealth LLC now owns 77,238 shares of the company’s stock worth $719,000 after purchasing an additional 12,878 shares during the period. Finally, Syon Capital LLC boosted its position in Haleon by 3.2% during the third quarter. Syon Capital LLC now owns 73,101 shares of the company’s stock worth $656,000 after purchasing an additional 2,292 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Trading Up 3.2%

Shares of HLN stock opened at $10.77 on Friday. The business has a 50-day moving average price of $10.43 and a two-hundred day moving average price of $9.80. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The firm has a market cap of $47.96 billion, a P/E ratio of 27.62 and a beta of 0.19.

Haleon Announces Dividend

The firm also recently declared a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be paid a dividend of $0.1307 per share. The ex-dividend date of this dividend is Friday, April 10th. This represents a dividend yield of 251.0%. Haleon’s dividend payout ratio (DPR) is 28.21%.

Analyst Ratings Changes

HLN has been the topic of several research reports. Deutsche Bank Aktiengesellschaft lowered shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. HSBC raised Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Haleon currently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.